Advertisement

Consider using selected antiepileptics to reduce the frequency of various types of headaches

  • Adis Medical WritersEmail author
Disease Management
  • 16 Downloads

Abstract

Antiepileptic drugs (AEDs) are among the best studied medications for the prevention of migraine and other headache disorders. The efficacy profiles of topiramate and valproate in headache prophylaxis are well established relative to those of other AEDs. Clinical data for other AEDs are generally limited, conflicting and/or show a lack of efficacy. Several factors, including the patient’s headache frequency and severity, tolerance of adverse events and the potential for pregnancy, should be considered when selecting an AED for headache prevention.

Notes

Compliance with ethical standards

Conflict of interest

The article was adapted from CNS Drugs 2018;32(8):735–46 [1] by employees of Adis/Springer, who are responsible for the article content and declare no conflicts of interest.

Funding

The preparation of this review was not supported by any external funding.

References

  1. 1.
    Marmura MJ, Kumpinsky AS. Refining the benefit/risk profile of anti-epileptic drugs in headache disorders. CNS Drugs. 2018;32(8):735–46.CrossRefGoogle Scholar
  2. 2.
    Costa C, Tozzi A, Rainero I, et al. Cortical spreading depression as a target for anti-migraine agents. J Headache Pain. 2013;14:62.CrossRefGoogle Scholar
  3. 3.
    Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78(17):1337–45.CrossRefGoogle Scholar
  4. 4.
    Ayata C, Jin H, Kudo C, et al. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol. 2006;59(4):652–61.CrossRefGoogle Scholar
  5. 5.
    Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial. Jama. 2004;291(8):965–73.CrossRefGoogle Scholar
  6. 6.
    Silberstein SD, Neto W, Schmitt J, et al. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol. 2004;61(4):490–5.CrossRefGoogle Scholar
  7. 7.
    Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007;47(2):170–80.CrossRefGoogle Scholar
  8. 8.
    Silberstein S, Lipton R, Dodick D, et al. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache. 2009;49(8):1153–62.CrossRefGoogle Scholar
  9. 9.
    Dodick DW, Silberstein S, Saper J, et al. The impact of topiramate on health-related quality of life indicators in chronic migraine. Headache. 2007;47(10):1398–408.CrossRefGoogle Scholar
  10. 10.
    Diener HC, Tfelt-Hansen P, Dahlof C, et al. Topiramate in migraine prophylaxis: results from a placebo-controlled trial with propranolol as an active control. J Neurol. 2004;251(8):943–50.CrossRefGoogle Scholar
  11. 11.
    Shaygannejad V, Janghorbani M, Ghorbani A, et al. Comparison of the effect of topiramate and sodium valporate in migraine prevention: a randomized blinded crossover study. Headache. 2006;46(4):642–8.CrossRefGoogle Scholar
  12. 12.
    Krymchantowski AV, Jevoux Cda C. Low-dose topiramate plus sodium divalproate for positive responders intolerant to full-dose monotherapy. Headache. 2012;52(1):129–32.CrossRefGoogle Scholar
  13. 13.
    Keskinbora K, Aydinli I. A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. Clin Neurol Neurosurg. 2008;110(10):979–84.CrossRefGoogle Scholar
  14. 14.
    Silberstein SD, Dodick DW, Lindblad AS, et al. Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine. Neurology. 2012;78(13):976–84.CrossRefGoogle Scholar
  15. 15.
    Li Y, Zhang Q, Qi D, et al. Valproate ameliorates nitroglycerin-induced migraine in trigeminal nucleus caudalis in rats through inhibition of NF-small ka, CyrillicB. J Headache Pain. 2016;17:49.CrossRefGoogle Scholar
  16. 16.
    Freitag FG, Collins SD, Carlson HA, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology. 2002;58(11):1652–9.CrossRefGoogle Scholar
  17. 17.
    Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia. 1997;17(2):103–8.CrossRefGoogle Scholar
  18. 18.
    Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113-e88.CrossRefGoogle Scholar
  19. 19.
    Bou Ghannam A, Pelak VS. Visual snow: a potential cortical hyperexcitability syndrome. Curr Treat Options Neurol. 2017;19(3):9.CrossRefGoogle Scholar
  20. 20.
    Silberstein S, Goode-Sellers S, Twomey C, et al. Randomized, double-blind, placebo-controlled, phase II trial of gabapentin enacarbil for migraine prophylaxis. Cephalalgia. 2013;33(2):101–11.CrossRefGoogle Scholar
  21. 21.
    Silberstein S, Saper J, Berenson F, et al. Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study. Neurology. 2008;70(7):548–55.CrossRefGoogle Scholar
  22. 22.
    Pascual J, Caminero AB, Mateos V, et al. Preventing disturbing migraine aura with lamotrigine: an open study. Headache. 2004;44(10):1024–8.CrossRefGoogle Scholar
  23. 23.
    Steiner TJ, Findley LJ, Yuen AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia. 1997;17(2):109–12.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations